SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

BioLineRx and Hemispherian Present Preclinical GLIX1 Data at ESMO 2026

The companies reported preclinical findings of synergy between GLIX1 and PARP inhibitors in HR-proficient ovarian cancer. The data included multiple cell lines and a patient-derived xenograft model.

BLRX

Related stories